JHL Starts European Trial of MabThera/Rituxan Biosimilar for RA

JHL Biotech has dosed the first patient in a European trial of JHL1101, a biosimilar to the Roche/Genentech rheumatoid arthritis treatment MabThera/Rituxan. JHL is a Taiwan-China biotech, formed by Genentech veterans, with a Wuhan, China manufacturing facility that is compliant with international regulations. Late in 2016, JHL struck a deal with Sanofi giving Sanofi rights to commercialize JHL1101 in China (though no trials have been announced). Sanofi paid $21 million upfront and invested $80 million in JHL stock for the rights in a deal valued at $257 million. More details.... Stock Symbols: (TWO: 6540) (NYSE: SNY) Share this with colleagues: // //